AIMP2 and acute myeloid leukemia: In the present study, we investigated the significance and clinical implications of AIMP2-DX2 by analyzing samples from the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) database, and validated results with a clinical patient cohort of acute myeloid leukemia (AML), which was found to have the most significant association with AIMP2-DX2/AIMP2 expression ratio in terms of cancer signaling pathways.